The Goldman Sachs Group Lowers Axon Enterprise (NASDAQ:AXON) Price Target to $625.00

Axon Enterprise (NASDAQ:AXON) had its target price cut by stock analysts at The Goldman Sachs Group from $720.00 to $625.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price target indicates a potential upside of 77.90% from the company’s current price.

AXON has been the topic of a number of other research reports. Needham & Company LLC dropped their price target on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. William Blair reaffirmed an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 3rd. Citigroup reaffirmed a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. UBS Group dropped their target price on shares of Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Finally, Morgan Stanley dropped their target price on shares of Axon Enterprise from $713.00 to $675.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Sixteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and a consensus target price of $755.88.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock opened at $351.33 on Wednesday. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. Axon Enterprise has a twelve month low of $347.28 and a twelve month high of $885.91. The stock has a market cap of $28.25 billion, a price-to-earnings ratio of 231.14, a P/E/G ratio of 8.36 and a beta of 1.61. The company’s fifty day moving average is $467.16 and its 200 day moving average is $569.82.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The company had revenue of $796.72 million for the quarter, compared to analysts’ expectations of $755.29 million. During the same quarter in the previous year, the firm posted $2.08 earnings per share. Axon Enterprise’s revenue for the quarter was up 38.5% on a year-over-year basis. Sell-side analysts forecast that Axon Enterprise will post 5.8 EPS for the current year.

Insiders Place Their Bets

In related news, Director Jeri Williams sold 157 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $490.00, for a total value of $76,930.00. Following the transaction, the director owned 1,159 shares in the company, valued at $567,910. The trade was a 11.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Isaiah Fields sold 2,000 shares of the business’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $535.01, for a total transaction of $1,070,020.00. Following the completion of the transaction, the insider owned 55,588 shares in the company, valued at approximately $29,740,135.88. The trade was a 3.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 13,855 shares of company stock valued at $7,109,828 over the last quarter. Company insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

Several institutional investors have recently made changes to their positions in the stock. Newbridge Financial Services Group Inc. raised its holdings in shares of Axon Enterprise by 2.8% during the second quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock valued at $421,000 after purchasing an additional 14 shares during the period. Vicus Capital raised its holdings in shares of Axon Enterprise by 3.7% during the third quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 14 shares during the period. Evergreen Capital Management LLC raised its holdings in shares of Axon Enterprise by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 15 shares during the period. Blue Trust Inc. raised its holdings in shares of Axon Enterprise by 2.5% during the third quarter. Blue Trust Inc. now owns 645 shares of the biotechnology company’s stock valued at $463,000 after purchasing an additional 16 shares during the period. Finally, NorthCrest Asset Manangement LLC raised its holdings in shares of Axon Enterprise by 5.4% during the third quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 16 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Key Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Wall Street reaffirmations and bullish notes tied to Axon Week and new AI products have supported the stock recently; several analysts reiterated buy ratings and highlighted AI-driven growth as a reason to view the pullback as a buying opportunity. Why Axon Stock Bounced Back After Falling 10%
• Positive Sentiment: Axon unveiled new AI offerings (Axon Vision, expanded Axon Assistant, Axon 911) at its annual conference intended to boost real-time public-safety data capabilities — a product roadmap that analysts say could drive multi-year revenue and margin improvement. Can Axon’s New AI Suite Reframe Its Real-Time Data Advantage Story for Investors (AXON)?
• Neutral Sentiment: Analysts trimmed price targets (Goldman Sachs and TD Cowen cut targets) but largely maintained constructive ratings — this reduces upside in the near term while leaving longer-term bull cases intact. Goldman Sachs price target update
• Neutral Sentiment: Sector/market news (e.g., coverage of peers and ad-tech moves) may be pulling investor attention and flows away from defensible growth stories, but these items are indirect for Axon. Macquarie sees AppLovin’s e-commerce push as a multi-year growth driver
• Negative Sentiment: New legal risk headlines tied to the company’s HQ and the cumulative effect of price-target cuts triggered fresh selling pressure; those headlines were cited by market coverage as a primary reason shares moved lower. Why Axon (AXON) Shares Are Trading Lower Today
• Negative Sentiment: Today’s decline was compounded by momentum selling and elevated volume after yesterday’s drop; market commentary and drop reports amplified the move. Axon Enterprise (AXON) Stock Drops Despite Market Gains

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.